Nasdaq Tumbles Over 300 Points; Chicago PMI Rises In March
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 31 2025
0mins
Source: Benzinga
Market Performance: U.S. stocks opened lower with the Nasdaq Composite dropping over 300 points, while energy shares rose by 1.1%. The Chicago PMI increased to 47.6 in March, surpassing market expectations.
Stock Movements: iCoreConnect Inc. and Corcept Therapeutics saw significant gains of 148% and 83%, respectively, while Damon Inc. and Vaxcyte, Inc. experienced sharp declines of 52% and 53%. European and Asian markets also closed lower.
Analyst Views on PCVX
Wall Street analysts forecast PCVX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCVX is 75.80 USD with a low forecast of 38.00 USD and a high forecast of 116.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 48.040
Low
38.00
Averages
75.80
High
116.00
Current: 48.040
Low
38.00
Averages
75.80
High
116.00
About PCVX
Vaxcyte Inc. is a clinical-stage vaccine innovation company. The Company is engaged in developing spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its pipeline includes VAX-31, a 31-valent PCV candidate advancing to a Phase III adult clinical program and being evaluated in a Phase II infant clinical program, which is being developed for the prevention of invasive pneumococcal disease (IPD) in adults and infants and is the broadest-spectrum pneumococcal conjugate vaccine (PCV) candidate in the clinic. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is being evaluated in a Phase II infant study. Its pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
